Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

RxSight (RXST) Equity Average (2020 - 2025)

RxSight's Equity Average history spans 6 years, with the latest figure at $275.8 million for Q4 2025.

  • For Q4 2025, Equity Average fell 1.23% year-over-year to $275.8 million; the TTM value through Dec 2025 reached $275.8 million, down 1.23%, while the annual FY2025 figure was $278.5 million, 26.11% up from the prior year.
  • Equity Average reached $275.8 million in Q4 2025 per RXST's latest filing, roughly flat from $277.0 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $280.3 million in Q1 2025 to a low of -$366.2 million in Q1 2021.
  • Average Equity Average over 5 years is $123.5 million, with a median of $155.2 million recorded in 2023.
  • The largest YoY upside for Equity Average was 226.73% in 2022 against a maximum downside of 35.72% in 2022.
  • A 5-year view of Equity Average shows it stood at $144.6 million in 2021, then tumbled by 35.72% to $92.9 million in 2022, then surged by 73.16% to $160.9 million in 2023, then surged by 73.53% to $279.2 million in 2024, then dropped by 1.23% to $275.8 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's Equity Average are $275.8 million (Q4 2025), $277.0 million (Q3 2025), and $278.7 million (Q2 2025).